利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

53 条记录 (耗时 0.03 秒)

    Physiologically active tetrapeptides
    3.
    发明授权
    Physiologically active tetrapeptides 失效
    生理活性四肽

    公开(公告)号：US4318847A

    公开(公告)日：1982-03-09

    申请号：US167586

    申请日：1980-07-11

    申请人： Hamao Umezawa ,  Takaaki Aoyagi ,  Tomio Takeuchi ,  Taiji Inui

    发明人： Hamao Umezawa ,  Takaaki Aoyagi ,  Tomio Takeuchi ,  Taiji Inui

    IPC分类号： C07K14/81 ,  A61K38/00 ,  A61K38/55 ,  A61P43/00 ,  C07C67/00 ,  C07C231/00 ,  C07C271/22 ,  C07K5/02 ,  C07K5/06 ,  C07K5/10 ,  C07C103/52

    CPC分类号： C07K5/06052 ,  C07C271/22 ,  C07K5/0202 ,  C07K5/06043

    摘要： This invention provides tetrapeptide derivatives of the formula (I): ##STR1## wherein R.sup.1 and R.sup.2 are methyl, 1-methylethyl, 2-methylpropyl, 1-hydroxyethyl, 2-carboxyethyl or 4-aminobutyl and Y is ##STR2## wherein R.sup.3 is methyl, 1-methylethyl, 2-methylpropyl, 1-methylpropyl, hydroxymethyl, 1-hydroxyethyl, carboxymethyl, 2-carboxyethyl, 4-aminobutyl, 3-guanidinopropyl, benzyl or p-hydroxybenzyl excluding the compounds in which R.sup.1 and R.sup.2 are each 1-methylethyl and also R.sup.3 is carboxymethyl or 2-carboxyethyl, the first and leftmost .beta.-amino acid moiety in said tetrapeptide derivatives having the (2S,3R)-configuration and a primary amino group and the second, third and fourth .alpha.-amino acid moieties in said tetrapeptide derivatives having the L-configuration. These compounds have an inhibitory activity on several types of aminopeptidases.

    摘要翻译： 本发明提供式（I）的四肽衍生物：其中R 1和R 2是甲基，1-甲基乙基，2-甲基丙基，1-羟乙基，2-羧基乙基或4-氨基丁基，Y是< 其中R 3为甲基，1-甲基乙基，2-甲基丙基，1-甲基丙基，羟甲基，1-羟乙基，羧甲基，2-羧乙基，4-氨基丁基，3-胍基丙基，苄基或对羟基苄基， 所述四肽衍生物中具有（2S，3R） - 构型和伯氨基的第一和最左侧的β-氨基酸部分和第二，第三和第四个α- 所述具有L-构型的四肽衍生物中的 - 氨基酸部分。 这些化合物对几种类型的氨基肽酶具有抑制活性。

    Physiologically active derivatives of esterastin
    9.
    发明授权
    Physiologically active derivatives of esterastin 失效
    酯酶的生理活性衍生物

    公开(公告)号：US4202824A

    公开(公告)日：1980-05-13

    申请号：US033359

    申请日：1979-04-26

    申请人： Hamao Umezawa ,  Takaaki Aoyagi ,  Tomio Takeuchi

    发明人： Hamao Umezawa ,  Takaaki Aoyagi ,  Tomio Takeuchi

    IPC分类号： C07D305/12 ,  C12P17/02

    CPC分类号： C12R1/465 ,  C07D305/12 ,  C12P17/02 ,  C12R1/56 ,  Y10S435/886

    摘要： Three, new physiologically active derivatives of esterastin are now provided, which inhibit the activity of esterase similarly to the parent esterastin and further exhibit a higher inhibiting activity against cholesterol esterase than the parent esterastin. These three new derivatives are tetrahydroesterastin which is produced by catalytic hydrogenation of esterastin; 3,5-di-hydroxy-2-hexylhexadeca-7,10-dienoic 1,3-lactone which is produced by alkaline hydrolysis of esterastin; and 3,5-di-hydroxy-2-hexylhexadecanoic 1,3-lactone which is produced either by alkaline hydrolysis of said tetrahydroesterastin or by catalytic hydrogenation of the product of the alkaline hydrolysis of esterastin.

    摘要翻译： 现在提供三种酯活性的新的生理活性衍生物，其类似于母体酯酶抑制酯酶的活性，并且进一步表现出比母体酯酶更高的对胆固醇酯酶的抑制活性。 这三种新的衍生物是通过酯酶的催化氢化制备的四氢西菌素 3,5-二羟基-2-己基十六碳-7,10-二烯-1,3-内酯，其通过酯酶抑制剂的碱性水解产生; 和3,5-二羟基-2-己基十六烷酸1,3-内酯，其通过所述四氢壳聚糖的碱水解或通过催化氢化酯酶的碱性水解产生。

    Physiologically active peptides and a process for preparation thereof
    10.
    发明授权
    Physiologically active peptides and a process for preparation thereof 失效
    生理活性肽及其制备方法

    公开(公告)号：US4126606A

    公开(公告)日：1978-11-21

    申请号：US834635

    申请日：1977-09-19

    申请人： Hamao Umezawa ,  Takaaki Aoyagi ,  Tomio Takeuchi ,  Masa Hamada

    发明人： Hamao Umezawa ,  Takaaki Aoyagi ,  Tomio Takeuchi ,  Masa Hamada

    IPC分类号： C07K5/02 ,  C07K5/083 ,  C07C103/52 ,  C12K1/04

    CPC分类号： C07K5/0202 ,  C07K5/0808 ,  Y10S435/886

    摘要： The present invention relates to new physiologically active peptides, derivatives thereof and a process for preparation thereof. In particular, it relates to new tetrapeptides designated amastatins A.sub.1, A.sub.2, A.sub.3, B.sub.1 and B.sub.2 and derivatives thereof which have an inhibitory effect on aminopeptidase A and also show stimulation of antibody formation and to a process for preparation thereof by cultivating a strain belonging to the genus Streptomyces.FIELD OF THE INVENTIONThe present invention relates to new physiologically active peptides, derivatives thereof and a process for preparation thereof. In particular, it relates to new tetrapeptides designated amastatins A.sub.1, A.sub.2, A.sub.3, B.sub.1 and B.sub.2 and derivatives thereof which have an inhibitory effect on aminopeptidase A and also show stimulation of antibody formation and to a process for preparation thereof by cultivating a strain belonging to the genus Streptomyces.DESCRIPTION OF THE PRIOR ARTSeveral physiologically active peptides or N-acylated peptides have been found in the culture broths by some of the present inventors. These substances, e.g. leupeptin, antipain, chymostatin and pepstatin, inhibit trypsin, papain, chymotrypsin and pepsin, respectively, but all these inhibitors have their effects on proteases which act in endo-type reaction. For further disclosures of these see Enzyme Inhibitors of Microbial Origin, Hamao Umezawa, University of Tokyo Press (1972) in Chapter IV, Inhibitors of Proteolytic Enzymes (pages 15-52) as follows:______________________________________ Peptides Page Number ______________________________________ Leupeptin 15 Antipain 29 Chymostatin 32 Pepstatin 34 ______________________________________ Bestatin, which has also been found in a microbial culture broth, inhibits an exo-type proteolytic enzyme, i.e. aminopeptidase B and leucine aminopeptidase, but it does not have any inhibitory effect on aminopeptidase A[J.Antibiotics 29, 97-103 and 600-601 and U.S. Pat. No. 4,029,547].SUMMARY OF THE INVENTIONThere are provided by the present invention the physiologically active peptides amastatins A.sub.1, A.sub.2, A.sub.3, B.sub.1 and B.sub.2 of the formula Ix--val--Val--Y Iwherein,X represents 3-amino-2-hydroxy-5-methylhexanoyl or 3-amino-2-hydroxy-4-methylhexanoyl residue,Val represents L-valyl residue, andY represents L-aspartic acid, L-glutamic acid or L-aspartic acid .alpha.-amide when X is 3-amino-2-hydroxy-5-methylhexanoyl residue, and L-glutamic acid or L-glutamic acid .alpha.-amide when X is 3-amino-2-hydroxy-4-methylhexanoyl residue, andThe amino group of Val adjacent to X being acylated with the carboxyl group of X to form an amide bond, the carboxyl group of said Val acylating the amino group of the other Val to form an amide bond, and the carboxyl group of the other Val acylating the amino group of Y to form an amide bond.There is further provided by the present invention a process for producing amastatins by cultivating a newly isolated Streptomyces sp. ME98-M3 (FERM p-3722) in a medium containing a carbon source and a nitrogen source under aerobic conditions until a substancial amount of physiological activity has been produced and by recovering thus produced amastatins from the culture broth.There are also provided by this invention various amastatin derivatives, such as salt, ester or N-acylated derivatives which are prepared by a conventional chemical process.Amastatins and derivatives thereof have a powerful inhibitory effect on aminopeptidase A and enhance antibody formation. Therefore, the present invention also provides an inhibitory agent of aminopeptidase A containing amastatins and a composition for enhancing antibody formation.DETAILED DESCRIPTION OF THE INVENTIONAmastatins A.sub.1, A.sub.2, A.sub.3, B.sub.1 and B.sub.2 of the present invention are structurally related to each other. They have similar physicochemical properties as follows: melting points, elementary analyses, pKa, Rf values in thin layer chromatography and migrations in high voltage paper electrophoresis which are summarized in Table I. TABLE I ______________________________________ Physicochemical properties of amastatins Amastatins A1 A2 A3 B1 B2 ______________________________________ mp 200-203 202-205 196-200 195-197 196-200 Elementary analysis Found C 53.06 53.00 54.30 54.00 54.31 H 8.32 7.91 8.01 8.40 7.98 O 14.61 27.17 11.16 23.02 11.21 N 23.30 11.67 26.10 14.18 26.00 Calculated C 53.26 53.15 54.08 54.19 54.08 H 8.30 8.07 8.25 8.48 8.25 O 14.79 11.81 11.47 22.97 11.47 N 23.65 26.98 26.20 14.36 26.20 For C.sub.21 H.sub.39 N.sub.5 O.sub.7 C.sub.21 H.sub.38 N.sub.4 O.sub.8 C.sub.22 H.sub.40 N.sub.4 O.sub.8 C.sub.22 H.sub.41 N.sub.5 O.sub.7 C.sub.22 H.sub.40 N.sub.4 O.sub.8 M.W. 473 474 488 487 488 pKa 3.8 2.8 3.0 3.7 3.0 4.0 4.2 4.2 Rf value* 0.47 0.46 0.54 0.55 0.52 Rm value** 0.52 0.51 0.53 0.54 0.53 ______________________________________ *Thin layer chromatography was performed with a silica gel plate and a solvent system of n-butanol-acetic acid-water(4:1:1). **Relative migration distance toward a cathode to alanine with a buffer solution of formic acid-acetic acid-water (25:75:900) at 3500v for 15min.Amastatins A.sub.1, A.sub.2, A.sub.3, B.sub.1 and B.sub.2 are soluble in water, methanol, acetic acid, pyridine and dimethyl sulfoxide, are slightly soluble in n-propanol and n-butanol and are almost insoluble in ethyl acetate, butyl acetate, diethyl ether, N-hexane, petroleum ether, benzene and chloroform. They give positive Rydon-Smith, ninhydrin and potassium permanganate reactions but negative Ehrlich and Sakaguchi reactions. No characteristic ultraviolet absorption is observed. Amastatins are stable in neutral, acidic and alkaline solutions. The inhibitory activity on aminopeptidase A was not decreased by heating the aqueous solution of pH 2, 7 or 9 at 60.degree. C. for 30 min.The following paragraphs describe the structures of amastatins which have thus far been characterized.Amastatin A.sub.1In the infrared absorption spectrum in potassium bromide the following absorption peaks are observed: 3300, 2980, 1710, 1665, 1635, 1550, 1470, 1405, 1355, 1225, 1150, 1090 and 700 (cm.sup.-1). Amino acid analysis of the acid hydrolysate of the compound in 6NHCl at 105.degree. C. for 18 hours gives valine, aspartic acid and a previously unknown amino acid with a molar ratio of 2:1:1. The new amino acid is isolated and purified by resin chromatography; its structure was suggested by NMR spectrum, IR spectrum, elementary analysis, pKa value, color reactions and chemical reactions, and confirmed by the chemical synthesis to be as follows: ##STR1## The NMR spectrum (100MHz. in D.sub.2 O) of amastatin A.sub.1 shows signals at .delta.1.1-1.4, 1.6-2.1, 2.2-2.6, 3.0-3.2, 3.85-3.95 and 4.4-4.7. For further characterization the peptide was acetylated at the N-terminal and dimethyl ester of N-acetylamastatin A.sub.1 was subjected to mass analysis. The result revealed that these amino acids were bound by amide bonds in sequence of N-acetylated new amino acid, valine, valine and aspartic acid dimethyl ester from the N-terminal. The above-mentioned pKa value of 3.8 indicates that the .beta.-carboxyl group of aspartic acid at the C-terminal of the peptide is free and the other .alpha.-carboxyl group forms an acid amide. The structure of amastatin A.sub.1 has thus been determined as follows: ##STR2##Amastatin A.sub.2The IR spectrum (KBr) gives the following peaks: 3400, 3250, 3030, 2930, 1700, 1650, 1620, 1530, 1465, 1390, 1220, 1160, 1085 and 700 (cm.sup.-1). Amino acid analysis provides the same result as in amastatin A.sub.1. The new amino acid has also been identified to be the same amino acid as that of amastatin A.sub.1 by the above-mentioned procedures. In the NMR spectrum of amastatin A.sub.2 the signals are observed at .delta. 1.2-1.5, 1.9-2.1, 2.3-2.7, 3.15-3.35, 3.85-4.15, 4.5-4.8 and 4.9-5.1. High-resolution mass spectrometric analysis of N-acetyl amastatin dimethyl ester demonstrates the same amino acid sequence as that of amastatin A.sub.1. The elementary analysis and the pKa values of 2.8 and 4.0, however, indicate that the two carbonyl groups of aspartic acid are carboxylic acid. The determined structure is as follows: ##STR3##Amastatin A.sub.3The IR spectrum (KBr) of the compound has the following peaks: 3430, 3280, 2950, 1710, 1660, 1630, 1540, 1467, 1395, 1225, 1090, 960 and 700 (cm.sup.-1). Amino acid analysis of the acid hydrolysate gives valine, glutamic acid and unknown amino acid. The new amino acid has been identified to be the same as in A.sub.1 and A.sub.2. The NMR spectrum of amastatin A.sub.3 shows the signals at .delta. 1.2-1.6, 2.3-2.7, 2.7-3.0, 3.1-3.4, 3.8-4.4 and 4.4-4.9. The high-resolution mass spectrum of N-acetyl amastatin A.sub.3 dimethyl ester indicates that N-acetylated new amino acid, valine, valine and glutamic acid dimethyl ester are bound in that order from the N-terminal to form amide bonds. The pKa values of 3.0 and 4.2 suggests that the .alpha.-and .gamma.-carbonyl groups of glutamic acid are carboxylic acid. From these results, the structure of amastatin A.sub.3 has been determined to be the following: ##STR4##Amastatin B.sub.1In the IR spectrum the following absorption bands are exhibited: 3340, 3000, 1710, 1665, 1640, 1550, 1475, 1405, 1315, 1230, 1160, 1090, 960 and 700 (cm.sup.-1). Amino acid analysis of the acid hydrolysate of the amastatin B.sub.1 in 6NHCl at 105.degree. C. for 18 hours gives valine, glutamic acid and unknown amino acid in the molar ratio of 2:1:1. The new amino acid has been isolated and purified, and characterized by NMR analysis. The structure of the amino acid has been found to be as follows by chemical synthesis. ##STR5##Amastatin B.sub.1 gives NMR spectrum (100MHz in D.sub.2 O) which shows the signals at .delta.0.6-1.0, 1.2-1.55, 1.6-2.3, 2.95-3.3, 3.8-4.4, 7.4-7.7 and 7.9-8.3. Analysis of high-resolution mass spectrum of N-acetyl amastatin B.sub.1 dimethyl ester indicates that N-acetylated new amino acid, valine, valine and glutamic acid dimethyl ester are bound by amide bonds in the sequence mentioned. It is suggested by the pKa value of 3.7 that the .gamma.-carbonyl group of glutamic acid bound at the C-terminal side is carboxylic acid and the other .alpha.-carbonyl group is an acid amide. Thus, the structure of amastatin B.sub.1 has been determined as follows: ##STR6##Amastatin B.sub.2In the IR spectrum the following absorption maxima are observed: 3400, 3260, 2940, 1700, 1655, 1625, 1550, 1450, 1400, 1315, 1225, 1150, 1090, 950 and 700 (cm.sup.-1). The same three amino acids are detected as in amastatin B.sub.1. The NMR spectrum (100MHz in D.sub.2 O) shows the signals at .delta. 1.1-1.55, 2.1-2.35, 2.37-2.75, 2.8-3.2, 3.8-4.05, 4.45-4.7, 4.75-4.9 and 4.9-5.0. The assignment of high-resolution mass spectrum of N-acetylated amastatin B.sub.2 dimethyl ester revealed that N-acetyl new amino acid, two valines and glutamic acid dimethyl ester are bound in that sequence by amide bonds. The pKa values of 3.0 and 4.2 indicate that the two carbonyl groups of glutamic acid are carboxylic acid. The structure of amastatin B.sub.2 is as follows: ##STR7##For further comfirmation of the structures of amastatins mentioned above, the novel peptides were chemically synthesized according to the following scheme: ##STR8##The physicochemical properties of amastatins obtained by the process according to the present invention are in good agreement with those of the chemically synthesized peptides. Therefore, the aforementioned structures of amastatins have been supported and confirmed.Amastatins contain one amino group and one carboxyl group in cases of A.sub.1, A.sub.3 and B.sub.1 and one amino group and two carboxyl groups in cases of A.sub.2 and B.sub.2 which are capable of forming salts, esters and acylated derivatives by conventional methods. The present invention thus includes such amastatin derivatives.Another aspect of this invention is to provide a process for preparation of the amastatins which comprises cultivating an amastatin-producing strain belonging to Genus Streptomyces in a suitable medium containing a carbon source and a nitrogen source under aerobic conditions until amastatins are substantially produced in the culture broth and recovering amastatins thus produced by conventional methods.The microorganism useful for the preparation of amastatins has been taxonomically characterized as Streptomyces sp. ME98-M3. It was isolated from a soil as a strain ME98-M3 and depositted in the Fermentation Research Institute, Japan as FERM p-3722 and in the American Type Culture Collection, Rockville, Maryland, as A.T.C.C. 31318. The morphological and cultural characteristics of the strain are set forth in the following paragraphs.1. MorphologyAerial hyphae with curved or loop-shaped termenals extend from branched substrate hyphae. Mature spore chain has 10 and more spores, which are 0.6-0.8 .times. 1.0-1.2.mu. with smooth surfaces.2. Growth on various mediaThe description in parenthesis follows the color standard "Color Harmony Manual" published by Container Corporation of America, USA.(a) Sucrose-nitrate agarVegitative growth: Dark yellow (3mc, Amber). No soluble pigment.Aerial mycelium: White (a, White) to pale yellowish brown (11/2 gc, Dusty Yellow)(b) Glucose-asparagine agarVegetative growth: Yellowish brown (3ne, Topaz Butterscotch). No soluble pigment.Aerial mycelium: Light gray (3fe, Silver gray).(c) Glycerine-asparagine agar (ISP medium No 5)Vegetative growth: Yellowish brown (3ne, Topaz Butterscotch). No soluble pigment.Aerial mycelium: Light gray (3fe, Silver gray).(d) Starch-inorganic salts agar (ISP medium No 4)Vegetative growth: Dark yellow (2ne, Mustard Gold) to pale yellow (2ne, Old Gold). No soluble pigment.Aerial mycelium: Yellowish gray (2ea, Lt. Wheat to Lt. Maze).(e) Tyrosine agar (ISP medium No 7)Vegetative growth: Grayish yellow brown (3ni, Clove Brown). No soluble pigment.Aerial mycelium: Grayish white (b, Oyster White) to yellowish gray (2ca, Lt. Ivory).(f) Nutrient agarVegetative growth: Pale yellowish brown (3pe, Amber Topaz). No soluble pigment.Aerial mycelium: None.(g) Yeast extract-malt extract agar (ISP medium No 2)Vegetative growth: Dark yellowish orange (3pg, Golden Brown). No soluble pigment.Aerial mycelium: White (a, White).(h) Oatmeal agar (ISP medium No 3)Vegetative growth: Dark yellow (2nc, Brite Gold to Nugget Gold). No soluble pigment.Aerial mycelium: Yellowish gray (2ca, Lt. Ivory).(i) Peptone-yeast extract-iron agar (ISP medium No 6)Vegetative growth: Colorless to pale yellowish brown (2ga, Colonial Yellow, Maize). No soluble pigment.Aerial mycelium: None.(j) Calcium malate agarVegetative growth: Colorless to pale yellow (11/2ia, Sunlight Yellow, Daffodil, Forsythia Jonquil). No soluble pigment.Aerial mycelium: White (a, White).All of the observations mentioned above were carried out after incubation at 27.degree. C.3. physiological properties(a) Growth temperature: Optimum temperature for growth is 24.degree.-30.degree. C. on maltose-yeast extract agar (maltose 10.0g, yeast extract 4.0g, agar 17.0g and deionized water 1000ml, pH 7.0). No growth below 15.degree. C. and over 45.degree. C.(b) Gelatin liquefaction on glucose-peptone-gelatin medium at 27.degree. C.: Liquefaction begins after 5 days incubation and is completed at 21 days. Weak liquefaction.(c) Starch hydrolysis on starch-inorganic salts agar (ISP medium No 4) at 27.degree. C.: Very weak hydrolysis begins after about 5 days incubation.(d) Peptonization and coagulation of skimmed milk at 37.degree. C.: Coagulation is completed after 4 days incubation and then moderate peptonization begins.(e) Melanin formation on tryptone-yeast extract broth (ISP medium No 1), peptone-yeast extract-iron agar (ISP medium No 6) and tyrosine agar (ISP medium No 7) at 27.degree. C.: Negative on all the media.(f) Utilization of carbohydrates of Pridham-Gottlieb agar at 27.degree. C.: L-Arabinose, xylose, glucose, D-fructose, sucrose, inositol and raffinose: Good growth; L-rhamnose and cellulose: No growth.(g) Liquefaction of calcium malate on calcium malate agar at 27.degree. C.: Negative.Based on the above-mentioned characteristics the strain ME 98-M 3 was identified as belonging to the genus Streptomyces and designated Streptomyces sp. ME 98-M 3.Production of amastatins by a strain belonging to genus Streptomyces was discovered by this invention. The present invention thus includes all strains belonging to genus Streptomyces which produce the tetrapeptides according to this invention and the above-mentioned Streptomyces sp. ME98-M3 strain comprises all natural and artificial mutants and all strains which may belong to the same species as the embodiment of the microorganism according to the present invention.Amastatins may be obtained by cultivation of the microorganism on a suitable medium and under suitable conditions. The media used for growth of the microorganisms in the present invention are the nutrient media known as suitable for growth of actinomycetes. As the carbon source any of those carbohydrates may be used which are normally employed in fermentation, such as glycerine, glucose, starch, dextrin, lactose, sucrose, maltose, molasses and fat may also be employed. The nitrogen may be furnished by any of those materials which are usually used, such as peptone, meat extract, corn steep liquor, cottonseed meal, nuts meal, soybean meal, yeast extract, casamino acid, sodium nitrate, ammonium nitrate and ammonium sulfate. The media may contain sodium chloride, phosphate salts, calcium carbonate and magnesium sulfate as inorganic nutrients. Other metal salts may also be added as a trace element if required. The cultivation or fermentation may be conducted in any type of aerobic cultivation such as shaking-flask-culture or tank-fermentor-culture. Submerged culture is preferred for large scale production. The fermentation temperature should be selected in the range that the microorganism produces amastatins and, in particular, a range from 25.degree. C. to 35.degree. C. is preferable. The fermentation is generally continued until a substantial amount of amastatins has been produced in the cultured broth.Amastatin production can be assayed by measuring the inhibitory activity on aminopeptidase A. The assay method employed is as follows: The aminopeptidase A activity was measured according to Nagatsu et al (I. Nagatsu, T. Nagatsu, T. Yamamoto and G. G. Glenner, Biochim. Biophys. Acta 198 255-70, 1970) with a modification. A mixture of 0.00075M glutamyl-.beta.-naphthylamide (1.0ml), 0.01M CaCl.sub.2 (0.2ml) 0.1M tris-Hcl buffer solution (pH 7.0, 0.6 ml) and a sample solution (0.1 ml) was incubated at 37.degree. C. for 3 min. Aminopeptidase A solution (0.1 ml., prepared by ammonium sulfate fractionation according to Nagatsu's method) was added to the mixture. The incubation at 37.degree. C. was continued for further 30 min. and then 1.0M acetate buffer solution, pH 4.2 (0.6ml) containing 0.1% fast garnet GBC salt (o-aminoazotoluene diazonium salt) and 10% Tween 20 was added. After 15 min. at room temperature absorbance (a) at 530nm of the mixture was measured. A mixture without the sample was also treated in the same way as the control (b). An inhibition rate (%) of aminopeptidase A was calculated from the following equation: ##EQU1## The concentrations necessary for 50% of the inhibition rate (ID.sub.50) in this assay tube were 0.65 mcg/ml in amastatin A.sub.1, 0.54mcg/ml in A.sub.2, 1.0mcg/ml in A.sub.3, 1.5mcg/ml in B.sub.1 and 1.0mcg/ml in B.sub.2, respectively.For example, a medium containing 2% glycerine, 2% dextrose, 1% Bactosoyton (Difco), 0.3% yeast extract, 0.2% (NH.sub.4).sub.2 SO.sub.4 and 0.2% CaCO.sub.3, pH7.4, was autoclaved and inoculated with spores and/or mycelium obtained from a slant culture of Streptomyces sp. ME98-M3. All the expressions "%" means weight per volume in this specification unless noted otherwise. Amastatins accumulation was detected after 3-7 days aerobic shaking culture at 27.degree. C.Table 2 shows the production of amastatins in shaking cultures with various media. The fermentation was carried out using 100ml of the medium in a 500ml-flask on a rotary shaker (180 RPM) at 29.degree. C. and 0.5ml of the broth was sampled for the assay. TABLE 2 __________________________________________________________________________Amastatin production in various culture media Amastatin production Composition Inhibition(%) of Initial Day Final No. Medium pH 1 2 3 4 7 pH __________________________________________________________________________1. Starch 1.0 6.7 31.5 8.6 Glucose 1.0 Soy bean meal 2.0 Yeast extract 0.5 2. Soy bean oil 2.0 7.1 26.9 9.0 Starch 0.5 Glucose 0.5 Soy bean meal 2.5 3. Glycerine 2.5 7.0 23.2 9.1 Meat extract 0.5 Polypeptone 0.5 4. Maltose 2.0 7.8 17.6 9.3 Meat extract 0.5 Polypeptone 0.5 Yeast extract 0.3 5. Starch 2.0 7.1 26.2 31.6 35.3 33.5 46.2 8.1 Glucose 1.0 Yeast extract 0.5 Casamino acid 0.5 6. Lactose 2.5 7.8 26.0 9.4 Yeast extract 0.5 Meat extract 0.5 Polypeptone 0.75 7. Sucrose 4.0 7.9 22.2 9.5 Protein hydrolysate 2.5 8. Glycerine 2.0 6.9 40.0 52.7 52.7 50.2 49.1 8.2 Dextrine 2.0 Soypeptone* 1.0 Yeast extract 0.3 9. Starch 2.0 7.1 38.5 45.7 47.5 40.3 48.3 8.9 Cotton seed meal 2.0 Corn steep liquor 1.0 10. Glycerine 3.0 7.2 19.5 8.6 Fish meal 2.0 __________________________________________________________________________ *Soypeptone is an enzymatic digest of soy bean meal Table 3 also shows the amastatin production in various media. The carbon and the nitrogen sources shown in the table were added to a basal medium containing 0.1% yeast extract, 0.1% NaCl, 0.05% K.sub.2 HPO.sub.4 and 0.05% MgSO.sub.4,7H.sub.2 O. The fermentation was conducted with 50ml medium in a 500ml flask on a rotary shaker (200 RPM) at 28.degree. C. the inhibitory activity was assayed with 0.02ml of the broth. TABLE 3 ______________________________________ Amastatin production in various media Composition of medium(%) Amastatin production Carbon after 4 days incubation No. source Nitrogen source pH Inhibition(%) ______________________________________ A Starch 3.0 Soy bean meal 2.0 6.7 18.0 B 3.0 Dry yeast 2.0 6.1 23.0 C 6.0 4.0 6.8 41.3 D 3.0 Cotton seed 2.0 6.5 25.9 meal E 6.0 4.0 6.5 58.6 F Glycerine 3.0 Soy bean meal 2.0 8.4 15.2 G 3.0 Dry yeast 2.0 8.2 16.0 H 3.0 Cotton seed 2.0 8.3 17.1 meal I Soy bean 3.0 Soy bean meal 2.0 7.4 43.1 oil J 6.0 4.0 6.8 55.1 K 3.0 Dry yeast 2.0 7.4 36.6 L 6.0 4.0 6.9 46.1 M 3.0 Cotton seed 2.0 6.4 30.4 meal N Starch 4.5 Dry yeast 4.0 6.4 57.1 Soy bean 1.5 meal O Cotton seed 4.0 6.5 61.8 meal P Starch 6.0 Cotton seed 4.0 6.0 64.3 meal (NH.sub.4).sub.2 SO.sub.4 0.2 ______________________________________ Soy bean meal : "Es-san meat", Ajinomoto Co. Cotton seed meal : "Pharmamedia These results show that the amastatin production varies with medium and incubation time. Preferable ingredients of the medium for amastatin production are glycerine, glucose, starch, soy bean oil, soy peptone, cotton sead meal, corn steep liquor, soy bean meal, yeast, casamino acid and ammonium sulfate.Jar and tank fermentors also give a good production of amastatin. For example, a tank-scale submerged culture was performed with 100 l of the medium P of Tab. 3 in a 200 l fermentor. After 96 hours incubation with 100 l/min. aeration and 200 RPM agitation, the highest production of amastatin was obtained and 0.1 ml of the broth at the time gave 50% inhibition in the above-mentioned assay method. Amastatin analogues, i.e. A.sub.1, A.sub.2, A.sub.3, B.sub.1 and B.sub.2 are usually coproduced in the fermentation broth. The ratio of each analogue in the broth depends on strain of microorganism, medium, cultural conditions and the like.Amastatins thus produced in the fermentation broth may be recovered by any method which may be employed for isolation and purification of peptide and conventional per se. For a small scale isolation the broth filtrate is evaporated in vacuo to dryness and the residue is extracted with a solvent that can dissolve peptide, such as methanol, ethanol, dimethyl sulfoxide, acetic acid or pyridine. For a large scale work amastatins are extracted from the broth filtrate with a solvent that can dissolve peptide and is immiscible with water, such as n-butanol. Concentration of the extracts gives crude powder of amastatins.Amastatins are satisfactorily isolated by adsorption on a conventional adsorvant, e.g. active carbon, organic adsorvant such as Amberlite XAD-4 (Rohm and Haas Co.) and cellulose, ion exchangers and silica gel. For example, active carbon was added in the broth filtrate (2%) to adsorb the peptides. The active carbon was filtered off and washed with water and then with 20-25 volumes of methanol at 40.degree. C. twice. More than 70% of amastatin in the broth was obtained by the methanol elution. Coproduced amastatin analogues are thus isolated as a crude powder of their mixture. Each amastatin analogue may effectively be fractionated and purified by chromatography. For this purpose cellulose is employed with a mixture of ethyl acetate-ethanol-ammonia (17:2:1) as a preferable solvent system. Isolation and purification are also possible by means of ion exchange resin based on the acidic and the basic functional groups of amastatins. Strongly basic or strongly acidic ion exchange resin is preferred.The present invention also includes a process for preparation of amastatin derivatives. Metal salts of amastatins are easily obtained by neutralization. Another salt form of amastatin is prepared by crystalization after addition of inorganic acid such as hydrochloric acid since amastatins have a free amino group. N-Acylated derivatives are obtained by the treatment with anhydride or halide of organic acid, such as acetic acid and propionic acid, under suitable conditions. Amastatins A.sub.2, A.sub.3 and B.sub.2 (22mg, 20mg and 20mg, respectively) were dissolved in water. Acetyl chloride was added to the solution at pH8.5 to acetylate the free amino group. N-Acetyl amastatins A.sub.2, A.sub.3 and B.sub.2 were obtained with the yields of 13mg, 11mg and 10mg, respectively. The NMR and the IR spectra confirmed that the products were N-acetylated amastatins. Esters of amastatins are prepared by esterification of the free carboxyl group with alcohol under suitable conditions. To N-acetyl amastatins A.sub.2, A.sub.3 and B.sub.2 (9mg, 8mg and 8mg, respectively) was added a mixture of thionyl chloride (0.5ml) and methanol (4ml) in an ice bath. The reaction mixture was kept in the ice for 30 min. and then at room temperature overnight. Evaporation in vacuo to dryness gave N-acetyl amastatin dimethyl ester (10mg of A.sub.2, 9mg of A.sub.3 and 9mg of B.sub.2 dimethyl esters, respectively). The NMR and the mass spectra confirmed that the products were dimethyl esters of N-acetyl amastatins A.sub.2, A.sub.3 and B.sub.2, respectively. Therefore, the present invention comprises processes for prepararions of salts, N-acylated derivatives and esters of amastatins.Amastatins of this invention possess a powerful inhibitory activity on aminopeptidase A as aforementioned. The inhibitory activity is so specific to aminopeptidase A that other aminopeptidases, such as aminopeptidase B are insusceptible to the tetrapeptides. Table 4 shows ID.sub.50 values of amastatins with aminopeptidase A and B. TABLE 4 ______________________________________ Inhibitions of aminopeptidase A and B by amastatins ID.sub.50 (mcg/ml) Amastatins Aminopeptidase A Aminopeptidase B ______________________________________ A.sub.1 0.65 > 100 A.sub.2 0.54 > 100 A.sub.3 1.0 > 100 B.sub.1 1.5 > 100 B.sub.2 1.0 > 100 ______________________________________ Aminopeptidase A is inhibited at the concentration of 0.5-1.5 mcg/ml but aminopeptidase B is not affected even in the presence of 100 mcg/ml amastatin.In addition to the inhibitory activity, the novel tetrapeptides of this invention show stimulation of humoral antibody formation. When mice (dd/Y) were immunized by intravenous injection of 10.sup.8 sheep red blood cells (SRBC), amastatins in saline were administered intraperitoneally or orally to the mice. Four days thereafter, the number of plaque forming cell (PFC) in spleen were enumerated by Jerne`S homolytic plaque technique (N. K. Jerne., A. A. Nordin and C. Henry: The agar plaque technique for recognizing antibody-producing cells, Cell-bond Antibodies. B. Amos and H. Koprowskied. pp. 109-122, Wister Institute Press, Philadelphia, 1963; N. K. Jerne and A. A. Nordine, Plaque Formation in Agar by Single Antibody-Producing Cells, Science, 140, pp 405, 1963).As shown in Table 5, the intraperitoneal injection of 1 to 1000 mcg/mouse or the oral administration of 10 to 1000 mcg/mouse of amastatin A.sub.2 led to increase the number of plaque-forming cells (PFC) about two or three times compared to the number of PFC in antigen alone. Table 5 ______________________________________ Effect of Amastatin on Antibody Formation to SRBC (I) in Mice Amastatin A2 Amst. administrated by dose/mouse* i.p. oral ______________________________________ PFC/spleen 10.sup.8 SRBC 0 149,000 125,000 " 1,000 .mu.g 235,000 153,000 " 100 283,000 192,800 " 10 504,000 286,400 " 1 264,800 102,700 ______________________________________ *injected i.p. at a time of immunization After amastatin A.sub.2 was injected intraperitoneal once a day to mice for 4 days, mice were immunized by intravenous injection of 10.sup.8 SRBC. Four days after the immunization, the number of antibody-forming cells in speen of mice were enumerated. As the result, intraperitoneal injection of 100 to 1000 mcg/mouse/day of amastatin A.sub.2 increased the number of PFC about two or three times compared to the number of PFC in antigen alone. Table 6 ______________________________________ Effect of Amastatin on Antibody Formation to SRBC (II) in Mice dose in .mu.g/mouse* SRBC** PFC/spleen ______________________________________ 0 110.sup.8 SRBC 76,000 1,000 " 121,000 100 " 138,000 10 " 196,000 1 " 58,000 ______________________________________ *days -4 .about. -1,i.p. **day 0, i.v. The effect of amastatin on primary antibody formation against SRBC in dissociated spleen cell cultures was examined according to the methods described by Mishell and Dutton. Spleen all cultures (1.5 .times. 10.sup.7) were prepared from spleens of CDF.sub.1 mice and were cultured with 10.sup.6 SRBC as antigen for 4 days at 37.degree. C. in 7% CO.sub.2 atmosphere. Amastatin was dissolved in medium and each concentration of amastatin in range of 0.0001 .mu.g to 1 .mu.g per culture was added at the time of the immunization (0 hour), 24, 48 or 72 hours after start of cultures. Four days after start of cultures, antibody formation of each culture was determined by enumeration in terms of PFC using the method described by Cuningham et al.As shown in Table 7, addition of 0.01 to 1 .mu.g of amastatin A.sub.2 to spleen cell culture 0 to 24 hours after the start of cultures increased the number of PFC. Table 7 ______________________________________ Addition of Amst. hrs. Amastatin after start of culture .mu.g/culture 0 24 48 72 ______________________________________ 10.sup.6 SRBC 0 2920 -- -- -- " 1 4420 3100 2280 2520 " 0.01 4200 2960 2380 3160 " 0.0001 2900 3080 2940 3080 ______________________________________ Also amastatin augmented establishment of delayed-type hypersensitivity (DTH) to SRBC. Female dd/Y mice were immunized by injection of 10.sup.8 SRBC in 0.05 ml of saline into the right hind footpad. Four days thereafter, the reaction was elicited by injection of 10.sup.8 SRBC into left hind footpad and the increase of the thickness of the left hind footpad was measured 24 hours later.Amastatin A.sub.2 was injected intraperitoneally once a day to the mice for four days before the immunization by 10.sup.8 SRBC. As shown in Table 8, amastatin A.sub.2 of 0.1 to 10 mcg/mouse/day enhanced the footpad response, but the injection of 100 mcg/mouse/day did not show any effect on the footpad response. Also intraperitoneal injection of 1 to 1000 mcg/mouse of amastatin A.sub.2 at the time of immunization did not enhance the footpad response. Table 8 ______________________________________ Influence of Amastatin on Establishment of Delayed-Type Hypersensitivity to SRBC in Mice Amst. injected on days or day dose in .mu.g/mouse -4 .about. -1 0* Increase of Footpad thickness ______________________________________ 0 10.2 9.0 1,000 -- 8.1 100 10.0 7.8 10 14.3 8.1 1 14.1 8.4 1 14.1 8.4 0.1 13.8 -- ______________________________________ *at a time of immunization The fact that amastatins enhance the antibody formation and the establishment of DTH shows possible application of the peptides to potentiate the host-defense system against bacterial and viral infections and also against cancer. Aminopeptidase A is one of the angiotensinases. Strong inhibition of the enzyme activity causes an inhibition of angiotensin II decomposition to maintain a certain concentration of angiotensin and to raise the blood pressure. Amastatins are possibly utilized for this purpose and also for potentiation of aldosterone activity.Amastatins of this invention show very low toxicity. Conventional aminopeptidase A inhibitors are highly toxic substances, e.g. metal chelating agents such as ethylenediamine tetracetic acid or o-phenanthroline or protein-modifying agents. Amastatins show the inhibition at lower concentration and have much lower toxicity than the conventional inhibitors. Table 9 gives the acute toxicity of amastatins in mouse by the intraperitoneal administration. TABLE 9 ______________________________________ Toxicity of amastatins Amastatins Dose (mg/kg, ip) Toxicity ______________________________________ A.sub.1 125 none A.sub.2 125 none A.sub.3 125 none B.sub.1 125 none B.sub.2 125 none ______________________________________

    摘要翻译： 本发明涉及新的生理活性肽及其衍生物及其制备方法。 具体地说，涉及对氨基肽酶A具有抑制作用的amastatin A1，A2，A3，B1和B2及其衍生物的新四肽，其也表现出抗体形成的刺激，以及通过培养属于 链霉菌属。